Promising New Compounds to Treat Advanced Prostate Cancer


MCTP researchers, in collaboration with Dr. Shaomeng Wang’s lab, have demonstrated the efficacy of a new set of compounds known as BET degraders for the treatment of metastatic castration-resistant prostate cancer. Patients with metastatic prostate cancer often develop resistance to standard therapies that target the androgen receptor signaling pathway. Through a different mechanism, BET degraders can disrupt the signaling of the androgen receptor, as well as the oncogene, MYC. In experiments, the BET degraders significantly suppressed cancer growth in prostate cancer cell lines and in mouse models that used patient-derived tumors, known as xenografts. These compounds warrant further investigation for future clinical development.

Read more…